Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia

Clement C. Zai*, Arun K. Tiwari, Nabilah I. Chowdhury, Zeynep Yilmaz, Vincenzo de Luca, Daniel J. Müller, Steven G. Potkin, Jeffrey A. Lieberman, Herbert Y. Meltzer, Aristotle N. Voineskos, Gary Remington, James L. Kennedy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. Results: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P =.003). Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted.

Original languageEnglish (US)
Pages (from-to)91-95
Number of pages5
JournalWorld Journal of Biological Psychiatry
Issue number1
StatePublished - Jan 2 2019


  • Tardive dyskinesia
  • neuregulin 1 (NRG1)
  • pharmacogenetics
  • receptor tyrosine-protein kinase erbB-4 (ERBB4)
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia'. Together they form a unique fingerprint.

Cite this